The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event

Abstract

Objective

An interleukin-beta antagonist reduces the risk of subsequent cardiovascular events in coronary patients with high-sensitivity C-reactive protein (hs-CRP) ≥2 mg/L. It remains to be defined how large the coronary population at inflammatory risk is, and what the predictors of elevated risk are.

Methods

A cross-sectional study investigated the proportion of patients with elevated hs-CRP (i.e. ≥2 mg/L) and the respective demographic and clinical predictors in 971 patients without concomitant inflammatory diseases who had been hospitalized with myocardial infarction (80%) and/or a revascularization procedure. Data were collected from hospital records, a self-report questionnaire and a clinical examination with blood samples.

Results

After 2–36 month follow-up, 39% (n = 378) had hs-CRP ≥ 2 mg/L, among whom 64% (n = 243) had low-density lipoprotein cholesterol (LDL-C) ≥1.8 mmol/L and 47% (n = 176) used a low-intensity statin regime. Only 24% had both LDL and hs-CRP at target range, 27% had elevation of both, whereas 12% had hs-CRP ≥ 2 mg/L and LDL-C < 1.8 mmol/L. Somatic comorbidity (odds ratio (OR) 1.3/1.0 point on the Charlson score), ≥1 previous coronary event (OR 2.4), smoking (OR 2.2), higher body mass index (OR 1.2/1.0 kg/m²), high LDL-C (OR 1.4/1.0 mmol/L) and higher anxiety scores (OR 1.1/1.0 point increase on the Hospital Anxiety and Depression Scale-Anxiety subscale score) were significantly associated with hs-CRP ≥2 mg/L in adjusted analyses.

Conclusions

Elevated hs-CRP was frequently observed after a coronary event and associated with unfavourable LDL-C and unhealthy lifestyles and psychosocial distress. Intensified statin therapy and strategies to target these modifiable factors are the encouraged first steps to reduce inflammation and improve LDL-C in these patients.

Keywords

High-sensitivity C-reactive protein prevalence predictors secondary prevention coronary heart disease low-density lipoprotein cholesterol statin therapy risk factor control demographic factors psychosocial factors

Get full access to this article

View all access options for this article.

References

Emerging Risk Factors C Kaptoge

Di Angelantonio

et al.

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet 2010; 375: 132–140.

Ridker

Cannon

Morrow

et al.

C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20–28.

Piepoli

Hoes

Agewall

et al.

2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37: 2315–2381.

McMurray

Kjekshus

Gullestad

et al.

Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A retrospective analysis. Circulation 2009; 120: 2188–2196.

Bohula

Giugliano

Cannon

et al.

Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 2015; 132: 1224–1233.

Cannon

Braunwald

McCabe

et al.

Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–1504.

Libby

Ridker

Hansson

. Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: From pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129–2138.

Ross

. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115–126.

Ridker

Everett

Thuren

et al.

Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119–1131.

10.

Sabatine

Morrow

Jablonski

et al.

Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115: 1528–1536.

11.

Munkhaugen

Sverre

Peersen

et al.

The role of medical and psychosocial factors for unfavourable coronary risk factor control. Scand Cardiovasc J 2016; 50: 1–8.

12.

Statistics Norway, https://www.ssb.no/befolkning/statistikker/flytting (25 May 2016, accessed 25 April 2017) and http://cvdnor.b.uib.no/files/2013/08/CVDNOR-Data-and-Quality-Report1.pdf (2013, accessed 25 May 2016).

13.

Peersen

Munkhaugen

Gullestad

et al.

Reproducibility of an extensive self-report questionnaire used in secondary coronary prevention. Scand J Public Health 2017; 45: 269–276.

14.

Stone

Robinson

Lichtenstein

et al.

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation 2014; 129(25 Suppl. 2): S1–S45.

15.

Kones

. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective. Drug Des Devel Ther 2010; 4: 383–413.

16.

Nissen

Tuzcu

Schoenhagen

et al.

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29–38.

17.

Ridker

. Residual inflammatory risk: Addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J 2016; 37: 1720–1722.

18.

Chirinos

Gurubhagavatula

Teff

et al.

CPAP, weight loss, or both for obstructive sleep apnea. N Engl J Med 2014; 370: 2265–2275.

19.

Estruch

. Anti-inflammatory effects of the Mediterranean diet: The experience of the PREDIMED study. Proc Nutr Soc 2010; 69: 333–340.

20.

Anderson

Sharp

Norton

et al.

Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev 2017; 6: CD007130–CD007130.

21.

Celano

Beale

Beach

et al.

Associations between psychological constructs and cardiac biomarkers after acute coronary syndrome. Psychosom Med 2017; 79: 318–326.

22.

Kumar

Nayak

. Psychological sequelae of myocardial infarction. Biomed Pharmacother 2017; 95: 487–496.

23.

Gimeno

Kivimaki

Brunner

et al.

Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med 2009; 39: 413–423.

24.

Wium-Andersen

Orsted

Nielsen

et al.

Elevated C-reactive protein levels, psychological distress, and depression in 73,131 individuals. JAMA Psychiatry 2013; 70: 176–184.

25.

Almeida

Norman

Hankey

et al.

The association between C-reactive protein concentration and depression in later life is due to poor physical health: Results from the Health in Men Study (HIMS). Psychol Med 2007; 37: 1775–1786.

26.

Bielas H, Meister-Langraf RE, Schmid JP, et al. Acute stress disorder and C-reactive protein in patients with acute myocardial infarction. Eur J Prev Cardiol. 2018; 25: 298–305.

27.

Wirtz

von Kanel

. Psychological stress, inflammation, and coronary heart disease. Curr Cardiol Rep 2017; 19: 111–111.

28.

Mommersteeg

Meeuwis

Denollet

et al.

C-reactive protein and fibrinogen in non-obstructive coronary artery disease as related to depressive symptoms and anxiety. J Psychosom Res 2014; 77: 426–429.

29.

Heldal M and Pedersen TR. Hjerteforum No. 1/ 2017 / vol. 30. Available at: http://legeforeningen.no/Fagmed/Norsk-cardiologisk-selskap/Hjerteforum1/b-2017/bHjerteforum-nr-1-2017/.

30.

Sabatine

Giugliano

Keech

et al.

Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.

31.

Canakinumab (Ilaris): Common drug review. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2016, https://www.ncbi.nlm.nih.gov/books/NBK409908/ (accessed 15 November 2017).

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.11 MB